OKEX
3.6.2019 13:12:18 CEST | Business Wire | Press release
OKEx, a world-leading cryptocurrency exchange, today announced its new listing of USDK, a US Dollar-pegged stablecoin co-launched by its strategic partner OKLink and Prime Trust. The new stablecoin will be listed on OKEx’s fiat-to-token (C2C) trading platform against six fiat currencies – CNY, VND, GBP, RUB, EUR and TRY, and spot trading platform with 11 trading pairs as below as well.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190603005420/en/
· BTC/USDK · ETC/USDK · TRX/USDK
· LTC/USDK · BCH/USDK · BSV/USDK
· ETH/USDK · EOS/USDK · USDT/USDK
· OKB/USDK · XRP/USDK
USDK is a ERC-20 stablecoin co-developed by OKLink, a blockchain technology company, and Prime Trust, a US-licensed trust company. Every USDK is backed by 1 USD from the Prime Trust Special Account. With a guaranteed 1:1 conversion rate between USDK and USD, the monetary value is 100% reserved. Also, an audit firm will provide monthly reports for maximum transparency to the public.
To celebrate the listing, OKEx will launch a 2-day campaign together with OKLink, offering a 1% conversion premium exclusively to OKEx’s users. During the promotion period, users can convert USDT to USDK at a special rate of 1 to 1.01.
“We are excited about the listing of USDK. With the support of the new stablecoin, we are one step forward to foster a new blockchain-driven economy, encouraging financial inclusion through achieving disintermediation,” said Andy Cheung, Head of Operations of OKEx. “We understand the pains in terms of third-party auditing. But with this new launch of a compliant stablecoin, we hope to provide our users a secure and reliable trading experience guaranteed by high transparency and regular audit. In the future, we are looking forward to incorporating USDK into more decentralized applications within OKEx’s ecosystem.”
END
About OKEx
OKEx is a world-leading digital asset exchange headquartered in Malta, offering comprehensive digital assets trading services including token trading, futures trading, perpetual swap trading and index tracker to global traders with blockchain technology. Currently, the exchange offers over 400 token and futures trading pairs enabling users to optimize their strategies. The platform provides a safe, reliable, and stable environment for digital asset trading, serving millions of customers from over 200 countries and regions.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190603005420/en/
Contact:
Jennifer Chow Jennifer.chow@okex.com Vivien Choi Vivien.choi@okex.com
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ThetaRay Named World’s Best Software Provider for AML and Sanctions Screening in the 2026 Euromoney Transaction Banking Awards5.11.2026 19:30:00 CET | Press release
Recognition caps standout year alongside ThetaRay’s Top 10 (#8) ranking in the 2026 Chartis Financial Crime and Compliance50 (FCC50) and category win for Explainable AI. ThetaRay, a global leader in AI-native financial crime compliance infrastructure, has been named The World’s Best Software Provider for AML and Sanctions Screening at the 2026 Euromoney Transaction Banking Awards. Evaluated by Euromoney’s editorial and research team, ThetaRay was recognized for technology excellence, verifiable performance, and advancing the modern transaction banking value chain. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261105714764/en/ The recognition reinforces ThetaRay’s standing as foundational compliance infrastructure for global institutions, closely following Chartis Research ranking ThetaRay #8 globally in the Financial Crime and Compliance50 (FCC50) 2026 report and naming the company a Category Winner for Explainable AI. “Our
Arthur D. Little: H1 2026 Private Capital Fundraising Strengthens While Market Sentiment Highlights Investor Shift to Europe over US and Asia5.11.2026 18:58:00 CET | Press release
H1 fundraising up 6% year-on-year as 43% of LPs see geopolitical volatility favouring European funds AI usage dominates industry attention, defence leads target investment themes Invest Europe, the association representing Europe’s private equity, venture capital and infrastructure sectors, as well as their investors, today released ‘Investing in Europe: Private Equity Activity H1 2026’ and ‘The Insight: State of the European Private Equity Industry 2026’, an annual market sentiment report published jointly with global management consultancy Arthur D. Little (ADL). Together, these show increased fundraising for European private equity and venture capital versus the same period last year, stronger investor allocation expectations for Europe, and declining appetite for the US and Asia. The sentiment report also demonstrates how AI is reshaping the industry and portfolio companies, while defence-related themes are topping GPs’ target investments. GPs (General Partners/fund managers of PE
Angelalign Appoints Marco Gadola as Senior Advisor5.11.2026 18:35:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel”) http://www.angelaligner.com, a global clear aligner leader, today announced that Marco Gadola has joined Angel as Senior Advisor. In this role, Marco will advise the Board and senior management on culture, strategy and governance. Marco, who has held many leadership positions, is well-known as a former CEO of Straumann Group, a leading global medical device company focused on dentistry. Marco said he is excited to join Angel. “I’ve followed Angel for 10 years and have seen how it has evolved,” he said, “It’s grown from a regional leader in innovative clinical solutions and high-quality products, to a worldwide organization trusted by orthodontic specialists, with an impressive innovation pipeline.” Fox Hu, CEO of Angel, said: “Angel has strong core capabilities, but we must continue to improve to serve orthodontists even better. We welcome Marco as an advocate for our customers and employees around the world and to help us build an outstan
Boomi Named a Visionary in the 2026 Gartner® Magic Quadrant™ for AI Agent Management Platforms5.11.2026 17:25:00 CET | Press release
Boomi governs agents, with flexibility across cloud, hybrid, and fully on-premises deployments behind the firewall. Boomi, the data activation company for AI, today announced it has been recognized as a Visionary in the 2026 Gartner® Magic Quadrant™ for AI Agent Management Platforms. Boomi delivers agent management capabilities through the Agent Control Plane. Boomi believes this placement reflects its approach to solving one of the biggest hurdles in turning AI into ROI, by providing critical AI infrastructure that connects, governs, and controls AI costs across agents and skills from native and third-party providers. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261105515847/en/ Boomi Named a Visionary in the 2026 Gartner® Magic Quadrant™ for AI Agent Management Platforms Key Takeaways Boomi has been recognized as a Visionary in the 2026 Gartner® Magic Quadrant™ for AI Agent Management Platforms. A complimentary copy of t
Biocodex Invests €15 Million in a New Industrial Platform for Live Biotherapeutic Products5.11.2026 16:04:00 CET | Press release
Biocodex, an independent French pharmaceutical company, announces a €15 million investment to develop an industrial platform in Beauvais, France, dedicated to Live Biotherapeutic Products (LBPs) derived from the microbiome. Building on more than 70 years of expertise in living microorganisms, microbiota, fermentation and pharmaceutical manufacturing, Biocodex aims to support its partners and, ultimately, its own programs, from research through to clinical and commercial production. The project aims to strengthen healthcare and industrial sovereignty in the field of next-generation microbiome-based therapies. Scientific advances in microbiome science are opening up new therapeutic perspectives, notably in oncology, inflammatory bowel diseases, certain rare diseases and women’s health. Moving from research to pharmaceutical production requires facilities adapted to living microorganisms and pharmaceutical requirements. Open to biotechnology companies worldwide, it will support LBP progra
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom